Portage Biotech Inc.

Equities

PRTG

VGG7185A1286

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:30:00 2024-05-10 pm EDT			5-day change	1st Jan Change
0.2523 ^USD	-3.78%		-6.90%	-86.14%

Apr. 15	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI
Apr. 12	Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	CI

Portage Biotech Inc. Reports Earnings Results for the Full Year Ended March 31, 2022

August 01, 2022 at 05:13 pm EDT

Portage Biotech Inc. reported earnings results for the full year ended March 31, 2022. For the full year, the company reported net loss was USD 16.87 million compared to USD 15.83 million a year ago. Basic loss per share from continuing operations was USD 1.29 compared to USD 1.35 a year ago. Diluted loss per share from continuing operations was USD 1.29 compared to USD 1.35 a year ago.

Latest news about Portage Biotech Inc.

Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	Apr. 15	CI
Portage Biotech Announces Plans to Expand Its Evaluation of Strategic Alternatives	Apr. 12	CI
Portage Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 28	CI
HC Wainwright Downgrades Portage Biotech to Neutral From Buy	Jan. 08	MT
Portage Biotech to Pause Drug Development in PORT-2 iNKT Program, to Cut Workforce	Jan. 04	MT
Portage Biotech to Evaluate Range of Strategic Options	Jan. 04	CI
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 28	CI
Portage Biotech Inc. Presents Updates on its iNKT and Adenosine Programs at the Society for Immunotherapy of Cancer's 38th Annual Meeting	Nov. 06	CI
Portage Biotech Inc. announced that it has received $5.3 million in funding	23-10-02	CI
Portage Biotech Inc. announced that it expects to receive $5.3 million in funding	23-09-28	CI
Portage Biotech in Keytruda Collaboration With Merck	23-09-05	DJ
Portage Biotech Inc. Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with Keytruda®? (Pembrolizumab) in Solid Tumors	23-09-05	CI
Portage Biotech Inc. Reports Earnings Results for the First Quarter Ended June 30, 2023	23-08-29	CI
HC Wainwright Cuts Price Target on Portage Biotech to $9 From $21, Maintains Buy Rating	23-08-02	MT
Cantor Fitzgerald Adjusts Price Target on Portage Biotech to $11 From $16, Maintains Overweight Rating	23-08-01	MT
Portage Biotech Inc. Reports Earnings Results for the Full Year Ended March 31, 2023	23-07-31	CI
Portage Biotech Inc. Announces First Patient Dosed in Phase 1A Trial of Portage-6 in Select Solid Tumors	23-06-26	CI
Portage Biotech Reports Updated Interim Data for Lead Inkt Engager, Port-2, in A Phase 1/2 Trial for the Treatment of Advanced Melanoma and Metastatic Non-Small Cell Lung Cancer At the 2023 American Society for Clinical Oncology Annual Meeting	23-06-05	CI
Portage Biotech Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	23-03-01	CI
HC Wainwright Adjusts Portage Biotech's Price Target to $21 From $22, Keeps Buy Rating	22-12-01	MT
Oppenheimer Adjusts Portage Biotech Price Target to $18 From $26, Maintains Outperform Rating	22-11-30	MT
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-29	CI
Portage Biotech Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	22-11-29	CI
Portage Biotech Inc. Presents Updated Data on the Phase 1/2 Trial Evaluating Port-2 At the Society for Immunotherapy of Cancer’S 37Th Annual Meeting	22-11-10	CI
Portage Biotech, Merck to Collaborate on Cancer Study	22-11-08	MT

Chart Portage Biotech Inc.

Duration

Period

More charts

Company Profile

Portage Biotech Inc. is a clinical-stage immuno-oncology company. The Company is advancing therapies to improve long-term treatment response and quality of life in patients with cancers. The Companyâs access to technologies coupled with biological mechanisms enables the identification of clinical therapies and product development strategies, which accelerate these medicines through the translational pipeline. The Companyâs portfolio consists of six diverse platforms, with programs including invariant natural killer T cell (iNKT) agonists, which includes PORT-2 and PORT-3, therapies that activate the innate and adaptive immune system. The Companyâs portfolio also includes small molecule adenosine inhibitors, such as PORT-6, PORT-7, PORT-8 and PORT-9, which represent of targeting the adenosine pathway. Within these six platforms, the Company has 14 products in development with multiple clinical readouts.

Sector

Biotechnology & Medical Research

Calendar

2024-07-28 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

0.2523 USD

Average target price

7 USD

Spread / Average Target

+2,674.49%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PORTAGE BIOTECH INC.	-86.14%	4.99M
MODERNA, INC.	+17.96%	44.96B
LONZA GROUP AG	+48.77%	41.85B
IQVIA HOLDINGS INC.	+1.17%	42.65B
CELLTRION, INC.	-4.27%	29.04B
ICON PUBLIC LIMITED COMPANY	+11.42%	26.08B
ALNYLAM PHARMACEUTICALS, INC.	-21.39%	19.03B
BIO-TECHNE CORPORATION	+4.86%	12.75B
MEDPACE HOLDINGS, INC.	+27.29%	12.06B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.50%	11.75B

Other Biotechnology & Medical Research